In the past decades, surveillance of patients with CHD has improved, leading to a 31% mortality reduction. These patients now grow older, thus increasing the prevalence of intra-atrial re-entrant tachycardia (IART), which is not only associated with severe clinical symptoms but also with cardiac transplant and an approximately 5-fold increased risk of death.
The substrate leading to atrial flutter in patients with CHD were several slow conduction areas and blocking regions (e.g. scars), cavotricuspid isthmus (CTI)-related flutter, or a combination of both. The most frequent circuit is CTI-related IART (51%), followed by non-CTI-related IART (27.7%), and a combination thereof (21.3%). Atrial substrate of arrhythmia can be analysed even without present arrhythmia, as exemplified in the Figure [1].
Figure: Atrial substrate of intra-atrial re-entrant tachycardia (IART). Adapted from [1,2]

Right: imaging from a patient with 2 scars in the posterior wall with scar tissue (grey) and healthy tissue (purple). Left: a counter-clockwise posterior wall IART is shown around the 2 scars. The circuit of arrhythmia could be predicted by electro-anatomical mapping in sinus rhythm.
Figure kindly provided by Dr Roca-Luque.
After ablation, patients with CHD suffer a high rate of IART recurrence. Notably, atypical flutter and complex anatomy are related with higher recurrence rates. Imaging of full cardiac and atrial anatomy using MRI and activation mapping can thus aid the selection of a suitable ablation procedure.
In summary, IART is a severe and frequent complication in patients with CHD and substrate mapping plays a key role in analysing circuits. Imaging and analysis of atrial substrate and cardiac and vascular anatomy before the ablation procedure are important as almost 10% of CHD patients have vascular or anatomic abnormalities. Dr Roca-Luque concluded that “imaging to predict IART substrate can help to improve ablation success.”
- Roca-Luque I. Ablation of atrial arrhythmias in patients with congenital heart disease: does cardiac imaging predict the response to therapy? EHRA 2021 Congress, 23-25 April.
- Roca-Luque I, et al. Europace 2018;20(2):353–361.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« High arrhythmic burden with left-bundle-branch block after TAVR with balloon-expandable valve Next Article
Antiarrhythmic drug treatment in children: evidence-based recommendations »
« High arrhythmic burden with left-bundle-branch block after TAVR with balloon-expandable valve Next Article
Antiarrhythmic drug treatment in children: evidence-based recommendations »
Table of Contents: EHRA 2021
Featured articles
Atrial Fibrillation and Direct Oral Anticoagulant
Predictors of young-onset atrial fibrillation
RACE 3 long-term results show fading benefit of targeted therapies in AF and HF
Deep dive into EAST-AFNET 4 results on early rhythm-control in atrial fibrillation
Cryo-FIRST study: improved AF and QoL outcomes with cryoballoon versus drug therapy
STROKESTOP: Benefits of systematic screening for atrial fibrillation
DOACs and bleeding: the role of antidotes
2021 EHRA practical guide: DOACs in pre-operative and bleeding patients
Atrial Ablation
Early rhythm-control ablation: insight from the CHARISMA registry
Personalised pulmonary vein isolation procedure feasible and effective
Pulmonary vein isolation: cryoballoon non-inferior to radiofrequency ablation
Diagnostic Tools
EHRA Practical Guide on cardiac imaging in electrophysiology
Novel diagnostic score accurately differentiates between athlete’s heart and ARVC
The precordial R-prime wave: a discriminator between cardiac sarcoidosis and ARVC
Limited added value of ECG-based mortality prediction in COVID-19 patients using machine learning
Devices
EHRA expert statement on pacemakers and intracardial devices: “watch out for the little old lady”
5-Year efficacy of subcutaneous implantable cardioverter defibrillator
Specific Populations
Individualised approaches key to success in resynchronisation therapy non-responders
Antiarrhythmic drug treatment in children: evidence-based recommendations
The importance of cardiac imaging in patients with congenital heart disease
Related Articles

June 16, 2021
Letter from the Editor
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com